Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192335 · ClinicalTrials.gov registry record · Phase 3
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
A Phase 3 study of Healthy, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 890
- Enrollment target
- 3
- Study locations
NCT00192335 is a Phase 3 study of Healthy that has completed, run by MedImmune. The registered enrollment target is 890 participants, above the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (38% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00192335, a Phase 3 study of Healthy, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 890 participants
- Enrollment target
- 3
- Study locations
Study Summary
* Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist * Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
Conditions Studied
Interventions
- BIOLOGICAL FluMist
- BIOLOGICAL CAIV-T
- BIOLOGICAL CAIVT
Study Locations (3)
Kansas
- Heart of America Research Institute - Shawnee Mission
Kentucky
- Kentucky Pediatric/Adult Research, Inc. - Bardstown
Texas
- R/D Clinical Research, Inc. - Lake Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192335
The ClinicalTrials.gov registry entry for NCT00192335 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 890 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (38% higher). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which FluMist is the first listed.
NCT00192335 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, Kentucky, Texas.
Frequently Asked Questions
What is clinical trial NCT00192335 about?
NCT00192335 is a clinical study titled "Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants". * Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist * Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
What is the current status of trial NCT00192335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 890 participants. The study started on 2004-07. Estimated completion is 2005-02.
What conditions does trial NCT00192335 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00192335?
The interventions under investigation include: FluMist (BIOLOGICAL), CAIV-T (BIOLOGICAL), CAIVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192335?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00192335 being conducted?
This trial has 3 study locations across Kansas, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.